Search

Transcription co-activator factor 20 (TCF20) is a regulator of transcription factors involved in extracellular matrix remodelling. In addition, TCF20 genomic variants in humans have been associated with impaired intellectual disability. Therefore, we hypothesized that TCF20 has several functions beyond those described in neurogenesis, including the regulation of fibrogenesis.

Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. Few genetic markers are associated with the outcome of T-ALL patients, independently of measurable residual disease (MRD) status after therapy. In addition, the prognostic relevance of genetic features may be modulated by the specific treatment used. We analyzed the genetic profile of 145 T-ALL patients by targeted deep sequencing. Genomic information was integrated with the clinicalbiological and survival data of a subset of 116 adult patients enrolled in two consecutive MRD-oriented trials of the Spanish PETHEMA (Programa Español de Tratamientos en Hematología) group. Genetic analysis revealed a mutational profile defined by DNMT3A/ N/KRAS/ MSH2/ U2AF1 gene mutations that identified refractory/resistant patients. Mutations in the DMNT3A gene were also found in the non-leukemic cell fraction of patients with T-ALL, revealing a possible mutational-driven clonal hematopoiesis event to prime T-ALL in elderly. The prognostic impact of this adverse genetic profile was independent of MRD status on day +35 of induction therapy. The combined worse-outcome genetic signature and MRD on day +35 allowed risk stratification of T-ALL into standard or high-risk groups with significantly different 5- year overall survival (OS) of 52% (95% confidence interval: 37-67) and 17% (95% confidence interval: 1-33), respectively. These results confirm the relevance of the tumor genetic profile in predicting patient outcome in adult T-ALL and highlight the need for novel gene-targeted chemotherapeutic schedules to improve the OS of poor-prognosis T-ALL patients.

The purpose of this study is to analyze the experiences of a group of higher education students in order to understand how they lived the construction of masculinity during their formative stage. Through A/r/tography methodology, we analyzed, using a qualitative method based on a biographical and interpretative perspectives, 72 bodygrafies performed by students of the Master of Psychopedagogy of the Universidad xxx as part of an exercise in visual self-representation. The results of the analysis allowed us to identify two great pedagogies in the construction process of masculinities: an anesthetic pedagogy and other sensitive and/or resistance pedagogy. The results obtained from the analysis of visual narratives show valuable experiences that encourage critical dialogues, from which useful guidelines are derived in order to overcome educational practices that perpetuate the model of traditional masculinity. In this way, the text reveals, by using the visual arts, a latent social reality and rises the reflection on how to promote a critical and transformative citizenship that overcome the conceptions of masculinity of traditional archetype, El presente texto tiene por objetivo analizar las experiencias vividas por un grupo de alumnado universitario con la intención de comprender cómo han vivido la construcción de la masculinidad durante su etapa formativa. Desde la metodología denominada ‘a/r/tografía’, empleando un enfoque cualitativo, y adoptando una perspectiva biográfica e interpretativa, se analizan 72 corpografías que fueron entregadas por alumnadodel Máster de Psicopedagogía de la Universidad xxx, como parte de un ejercicio de auto-representación visual. Los resultados del análisis permiten identificar dos grandes pedagogías en la formación de masculinidades por parte de los participantes: una pedagogía anestesiante y otra pedagogía sensible y/o de la resistencia. Los resultados obtenidos del análisis de las narraciones visuales permiten dar a conocer valiosas experiencias que fomentan diálogos críticos, de las que se derivan pautas útiles con el objeto de superar prácticas educativas que perpetúen el modelo de masculinidad tradicional. De esta forma, el presente texto revela, a través de las artes visuales, una realidad social latente y da pie a reflexionar sobre cómo cimentar una ciudadanía crítica y transformadora que deje atrás las concepciones de masculinidad de arquetipo tradicional

La ponencia trata sobre el cuerpo y las cosas en educación y lo hace en forma de collage, combinando ideas y postulados procedentes de diferentes tradiciones de pensamiento y culturas científicas desde un núcleo ordenador común: la educación entendida como una acción de apertura al mundo que reposa, como señala Le Breton (2000, p. 41), en «un saber estar, un saber ver, un saber escuchar, una apertura al mundo del sentido y de los sentidos». Como una acción corporeizada y, por ello, afectiva, sensorial y móvil en diálogo con las cosas. En primer lugar, trataremos sobre los términos cuerpo y cosas con la intención de acotar mínimamente la rica red semántica que ambos vocablos comportan. Seguidamente, se abordarán las claves que podrían explicar el giro corporal y material en las agendas de la investigación sociohumanística y en la educativa. A continuación, nos detendremos en el cuerpo como cosa para inferir, a partir de ellos, algunas implicaciones socioantropológicas y educativas. La última parre de la ponencia reflexiona acerca de las pedagogías sensibles en clave fenomenológica. Finalmente, en apretada síntesis, se resaltarán algunas conclusiones en un intento de involucrar a nuestros lectores en nuestras reflexiones y dialogar con ellos.

Promising results have been shown with the combination of ponatinib and chemotherapy in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT) in newly diagnosed Ph+ ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after alloHSCT. Primary end points were hematologic and molecular response before alloHSCT and event-free survival (EFS), including molecular relapse as event. Thirty patients (median age, 49 years; range, 19-59 years) entered the trial. All exhibited hematologic response, and alloHSCT was performed in 26 patients (20 in complete molecular response and 6 in major molecular response). Only 1 patient died (of graft-versus-host disease), and 5 patients exhibited molecular relapse after alloHSCT. No tyrosine kinase inhibitor was given after HSCT in 18 of 26 patients. Twenty-nine patients are alive (median follow-up, 2.1 years; range, 0.2-4.0 years), with 3-year EFS and overall survival (OS) of 70% (95% confidence interval, 51-89) and 96% (95% confidence interval, 89-100), respectively. Comparison of the PONALFIL and the ALLPh08 (Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph [BCR-ABL] Positive; same schedule, using imatinib as the tyrosine kinase inhibitor) trials by propensity score showed significant improvement in OS for patients in PONALFIL (3-year OS, 96% vs 53%; P = .002). The most frequent grade 3 to 4 adverse events were hematologic (42%), infectious (17%), and hepatic (22%), with only one vascular occlusive event. The combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph+ ALL. Cross-trial comparison suggests improvement vs imati

The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).